BRPI0721216A2 - Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida - Google Patents

Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida

Info

Publication number
BRPI0721216A2
BRPI0721216A2 BRPI0721216-0A2A BRPI0721216A BRPI0721216A2 BR PI0721216 A2 BRPI0721216 A2 BR PI0721216A2 BR PI0721216 A BRPI0721216 A BR PI0721216A BR PI0721216 A2 BRPI0721216 A2 BR PI0721216A2
Authority
BR
Brazil
Prior art keywords
hepatotoxidity
acetaminofen
compositions
reduced
side effects
Prior art date
Application number
BRPI0721216-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Eric M Soderling
Original Assignee
Eric M Soderling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eric M Soderling filed Critical Eric M Soderling
Publication of BRPI0721216A2 publication Critical patent/BRPI0721216A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0721216-0A2A 2006-12-09 2007-12-08 Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida BRPI0721216A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87374306P 2006-12-09 2006-12-09
US11/952,556 US20080139654A1 (en) 2006-12-09 2007-12-07 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
PCT/US2007/025167 WO2008073344A1 (en) 2006-12-09 2007-12-08 Acetaminophen compositions having minimized side effects including reduced hepatotoxicity

Publications (1)

Publication Number Publication Date
BRPI0721216A2 true BRPI0721216A2 (pt) 2014-12-02

Family

ID=39498949

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0721216-0A2A BRPI0721216A2 (pt) 2006-12-09 2007-12-08 Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida

Country Status (13)

Country Link
US (1) US20080139654A1 (enExample)
EP (1) EP2094253A4 (enExample)
JP (1) JP2010513229A (enExample)
KR (1) KR20090089867A (enExample)
CN (1) CN101588797A (enExample)
AU (1) AU2007332812A1 (enExample)
BR (1) BRPI0721216A2 (enExample)
CA (1) CA2671490A1 (enExample)
EA (1) EA200970449A1 (enExample)
IL (1) IL199056A0 (enExample)
MX (1) MX2009006177A (enExample)
WO (1) WO2008073344A1 (enExample)
ZA (1) ZA200904764B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20080187A1 (it) * 2008-02-07 2009-08-08 Velleja Res Srl Formulazioni di amminoacidi per la prevenzione del danno epatico da paracetamolo
US20110014285A1 (en) * 2009-07-15 2011-01-20 Herzenberg Leonore A N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen
TR201007652A2 (tr) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Sinerjik etki.
WO2013044085A1 (en) * 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
WO2014159994A1 (en) * 2013-03-13 2014-10-02 Nbip, Llc Compositions and methods for removing the odor from glutathione when mixed in an aqueous system
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
AU2017208123B2 (en) * 2016-01-11 2022-04-21 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
KR101962518B1 (ko) 2016-09-13 2019-03-26 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 아세트아미노펜 유도 간 독성 예방 또는 치료용 조성물
WO2018089400A1 (en) * 2016-11-09 2018-05-17 The Feinstein Institute For Medical Research Iguratimod as an mif inhibitor
KR102813413B1 (ko) 2019-08-27 2025-05-27 주식회사 엘지에너지솔루션 단위셀의 두께측정장치 및 두께측정방법
US11590090B2 (en) * 2019-09-14 2023-02-28 Anzen Pharmaceuticals, LLC Acetaminophen formulation with protection against toxic effects of overdose
EP4238559A1 (en) 2022-03-04 2023-09-06 Centre Hospitalier Universitaire de Caen Normandie Combinations of acetaminophen and n-acetyl cysteine for the treatment of pain and fever

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474757A (en) * 1992-10-16 1995-12-12 Rutgers University Prevention of acetaminophen overdose toxicity with organosulfur compounds
GR1002731B (el) * 1996-10-21 1997-07-04 Uni-Pharma ����� ������ �.�.�.�. ������������ ���������� Φαρμακευτικα ενεσιμα διαλυματα περιεχοντα συνδυασμους παρακεταμολης με αλλες δραστικες ουσιες.
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration

Also Published As

Publication number Publication date
KR20090089867A (ko) 2009-08-24
ZA200904764B (en) 2012-12-27
CN101588797A (zh) 2009-11-25
JP2010513229A (ja) 2010-04-30
EA200970449A1 (ru) 2009-08-28
MX2009006177A (es) 2009-08-31
EP2094253A4 (en) 2010-02-10
US20080139654A1 (en) 2008-06-12
AU2007332812A1 (en) 2008-06-19
CA2671490A1 (en) 2008-06-19
IL199056A0 (en) 2010-03-28
EP2094253A1 (en) 2009-09-02
WO2008073344A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
BRPI0721216A2 (pt) Composições de acetaminofen com efeitos colaterais minimizados e hepatotoxidez reduzida
BRPI0716325A2 (pt) Composição antimicrobianas
EP2067800A4 (en) POLYORGANOSILOXANE COMPOSITION
DK1849352T3 (da) Mejetærsker
ATE443753T1 (de) Nuancierungsmittel
AR062844A1 (es) Composicion pesticida
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
EP2087096A4 (en) MODIFIED CYANOBACTERIA
EP3450425C0 (en) PERCARBOXYLIC ACID COMPOSITION
DE602007012130D1 (de) Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
BRPI0719250A2 (pt) Métodos e composições com opalescência reduzida.
EP2053117A4 (en) LUBRICANT COMPOSITION
EP2043136A4 (en) FILMING COMPOSITION
BRPI0716881A2 (pt) Composições tópicas
EP2097355A4 (en) ANTIMICROBIAL COMPOSITION
BRPI0716458A2 (pt) Composição de vulcanizado
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
FR2899479B1 (fr) Composition cicatrisante
EP2003187A4 (en) LUBRICANT COMPOSITIONS
ATE546437T1 (de) Aminomethyl-4-imidazole
DK1978944T3 (da) Blød-gelatine-kapselformulering
EP2006359A4 (en) GAS OIL COMPOSITION
BRPI0718141A2 (pt) Composições de frangrâncias
DE502006006067D1 (de) Ng
EP2054074A4 (en) MODIFIED ERYTHROPOIETIN

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]